Journal ArticleDOI
The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.
TLDR
The data suggest that tumor-infiltrating immune cells in lung cancer are likely to be important determinants of both prognosis and response to immunotherapies.About:
This article is published in Biomedicine & Pharmacotherapy.The article was published on 2017-11-01. It has received 219 citations till now. The article focuses on the topics: Immunotherapy & Immune system.read more
Citations
More filters
Journal ArticleDOI
Tumour-associated neutrophils in patients with cancer
Merav E. Shaul,Zvi G Fridlender +1 more
TL;DR: The evidence correlating the neutrophil-to-lymphocyte ratio with prognosis is described, followed by a discussion on the predictive value of TANs, which remains debatable, with conflicting data from different cancer types.
Journal ArticleDOI
Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer
TL;DR: The weight of evidence supports a positive role for TIL-B and PC in antitumor immunity, suggesting that enhancement of these responses should be considered in the design of cancer immunotherapies.
Journal ArticleDOI
Immune infiltration in renal cell carcinoma.
Shichao Zhang,Erdong Zhang,Jinhua Long,Zuquan Hu,Jian Peng,Lina Liu,Fuzhou Tang,Long Li,Yan Ouyang,Zhu Zeng +9 more
TL;DR: Tumor‐infiltrating immune cells (TIICs) are important determinants of prognosis in RCC meanwhile reveals potential targets and biomarkers for immunotherapy development.
Journal ArticleDOI
Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study
TL;DR: It is suggested that subtle differences in the cellular composition of the immune infiltrate in CRC appear to exist, and these differences are likely to be important determinants of both prognosis and response to treatment.
Journal ArticleDOI
Immune microenvironment composition in non-small cell lung cancer and its association with survival.
Menno Tamminga,Thijo J N Hiltermann,Ed Schuuring,Wim Timens,Rudolf S N Fehrmann,Harry J.M. Groen +5 more
TL;DR: In non‐small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival and the immune infiltrate composition in NSCLC patients was evaluated.
References
More filters
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI
Cancer-related inflammation.
TL;DR: The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Journal ArticleDOI
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman,Chih Long Liu,Michael R. Green,Andrew J. Gentles,Weiguo Feng,Yue Xu,Chuong D. Hoang,Maximilian Diehn,Arash Ash Alizadeh +8 more
TL;DR: CIBERSORT outperformed other methods with respect to noise, unknown mixture content and closely related cell types when applied to enumeration of hematopoietic subsets in RNA mixtures from fresh, frozen and fixed tissues, including solid tumors.
Journal ArticleDOI
Neoantigens in cancer immunotherapy
TL;DR: Observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Journal ArticleDOI
The future of immune checkpoint therapy
Padmanee Sharma,James P. Allison +1 more
TL;DR: The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment, which will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.